Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Interstitial cystitis (IC) is a prolonged condition that causes bladder pressure, pain, and, in some cases, pelvic pain. The symptoms of interstitial cystitis may cause an impact on one’s social life, physical activity, sleep, and even on the ability to work. The disease tends to effect women more than the men. Common symptoms of interstitial cystitis include bladder pain and pressure, frequent urination, pain in vagina or vulva in case of women, and pain in scrotum or testicles in case of men. It is difficult to diagnose, therefore even though treatments can improve one's quality of life, there is no optimal cure.

The global interstitial cystitis drugs market is estimated to be US$ 206.6 Million in 2021 and is expected to reach US$ 323.4 million by 2028 to grow at a CAGR of 6.6% during the forecast period (2021 –2028).

The increasing number of product launches and drug approvals are expected to drive the market growth over the forecast period.

Key players are focusing on product launches and drug approval by regulatory authorities, which are expected to propel the market growth over the forecast period. For instance, in December 2019, the U.S. Food and Drugs Administration (FDA) issued a draft guidance outlining suggestions for the clinical development of new drugs to treat patients with interstitial cystitis/bladder pain syndrome (IC/BPS). This ultimately encourages sponsors of biopharmaceutical companies to manufacture and market more drugs related to interstitial cystitis or bladder pain syndrome.

Figure 1. Global Interstitial Cystitis Drugs Market Value (US$ Mn), and Y-o-Y Growth (%), 2017-2028

Interstitial Cystitis Drugs  | Coherent Market Insights

Interstitial Cystitis Drugs Market – Regional Analysis

North America region is expected to dominate with the largest market share in the global interstitial cystitis drugs market, owing to the increasing cases of interstitial cystitis in the region and the rise in research funding & advances in the diagnostic imaging of interstitial cystitis. For instance, the prevalent population of interstitial cystitis in the U.S. was reported to be 5,894,905 in 2018, which is expected to increase in the forecast period.

request-sample

Interstitial Cystitis Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 206.6 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 6.6% 2028 Value Projection: US$ 323.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drugs: Pentosan Polysulfate Sodium, Dimethyl Sulfoxide, Others
  • By Route of Administration: Oral Therapy, Intravesical Therapy
  • By End User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Bayer AG, Eli Lilly and Co., Johnson & Johnson, Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Growth Drivers:
  • High prevalence of interstitial cystitis
  • Increasing awareness of interstitial cystitis
  • Advent of gene therapy 
  • Rising grants for research on interstitial cystitis
Restraints & Challenges:
  • Lack of approved drugs 
  • Side-effects of available medications
  • Low diagnosis rate of interstitial cystitis 
  • High treatment cost

Global Interstitial Cystitis Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported in the U.S. as of July 14, 2021 are approximately 187,519,798 with around 4,049,372 deaths. The coronavirus or COVID-19 outbreak that started from Wuhan, China, and has spread across continents, affecting various industries globally. Continuous pain symptoms due to IC are also known to produce psychological disorders, such as anxiety and depression. Moreover, the spread of COVID-19 pandemic added to the distress of IC patients by causing psychological symptoms such as fear, sadness, boredom, frustration, and anger. A multidisciplinary approach offers a personalized treatment for IC patients by providing a web-mediated counseling intervention for patients and their caregivers. This can favor a relationship-based process of change aimed at an improvement in quality of life.

Figure 2. Global Interstitial Cystitis Drugs Market Share (%), By Drug 2021

Interstitial Cystitis Drugs  | Coherent Market Insights

Global Interstitial Cystitis Drugs Market: Restraint

The lack of approved drugs, side-effects due to available medications, low diagnosis rate of interstitial cystitis, and the high treatment cost are expected to restrain the market during the forecast period. In April 2020, the Food and Drug Administration (FDA) Trusted Source requested that all forms of prescription and over-the-counter (OTC) Ranitidine (Zantac) drugs should be removed from the U.S. market. This recommendation was made due to unacceptable levels of NDMA (a probable carcinogen (or cancer-causing chemical)) in some ranitidine drugs, which could negatively affect patients suffering from IC.

Key Players

Major players operating in the global interstitial cystitis drugs market include Bayer AG, Eli Lilly and Co., Johnson & Johnson, Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Interstitial Cystitis (IC) also called as painful bladder syndrome, is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. The bladder expands until it is full and then gives signal to the brain that it is time to urinate, communicating through pelvic nerves. With IC, these signals get mixed up and then patient feels the need to urinate more often and with smaller volumes of urine than most people. The IC disease most often affects women and can has a long-lasting impact on the quality of life. Although there is no cure, medications, and other therapies may offer some relief.

There are two types of IC such as non-ulcerative IC, which is found in 90% of the population suffering from IC. It is characterized by pinpoint hemorrhages called glomerulations. Another type of IC is Ulcerative IC, which comprises of about 5-10% of the patient population. It is mainly characterized by Hunner’s ulcers and the patches that bleed on bladder walls. Hunner’s ulcers, also called “Hunner’s lesions” or “Hunner’s patches”, are a sub type of IC and are not ulcers in the usual sense. They are distinctive areas of inflammation on the bladder wall that characterize the “classic” form of IC, and it affects only about 5 to 10 percent of patients suffering from IC.

Market Dynamics

The high prevalence of interstitial cystitis is driving the global interstitial cystitis drugs market. Patients suffering from interstitial cystitis experience symptoms such as lower urinary tract issues and bladder pain. Women are highly affected by this condition. According to Patnaik et al., 2017, prevalence estimates suggest that 45 per 100,000 females and 8 per 100,000 men are diagnosed with IC in North America.

Key features of the study:

  • This report provides in-depth analysis of the global interstitial cystitis drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global interstitial cystitis drugs market based on the following parameters – Company Highlights, Product Portfolio, Key Highlights, Financial Performance, and Market Strategies.
  • Key companies covered as a part of this study include Bayer AG, Eli Lilly and Co., Johnson & Johnson, Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global interstitial cystitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interstitial cystitis drugs market

Detailed Segmentation:

  • Global Interstitial Cystitis Drugs market, By Drugs:
    • Pentosan Polysulfate Sodium
    • Dimethyl Sulfoxide
    • Others
  • Global Interstitial Cystitis Drugs market, By Route of Administration:
    • Oral Therapy
    • Intravesical Therapy
  • Global Interstitial Cystitis Drugs market, By End User:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Interstitial Cystitis Drugs Market, By Region:  
    • North America
      • By Drugs
        • Pentosan Polysulfate Sodium
        • Dimethyl Sulfoxide
        • Others
      • By Route of Administration
        • Oral Therapy
        • Intravesical Therapy
      • By End User
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drugs
        • Pentosan Polysulfate Sodium
        • Dimethyl Sulfoxide
        • Others
      • By Route of Administration
        • Oral Therapy
        • Intravesical Therapy
      • By End User
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drugs
        • Pentosan Polysulfate Sodium
        • Dimethyl Sulfoxide
        • Others
      • By Route of Administration
        • Oral Therapy
        • Intravesical Therapy
      • By End User
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drugs
        • Pentosan Polysulfate Sodium
        • Dimethyl Sulfoxide
        • Others
      • By Route of Administration
        • Oral Therapy
        • Intravesical Therapy
      • By End User
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drugs
        • Pentosan Polysulfate Sodium
        • Dimethyl Sulfoxide
        • Others
      • By Route of Administration
        • Oral Therapy
        • Intravesical Therapy
      • By End User
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drugs
        • Pentosan Polysulfate Sodium
        • Dimethyl Sulfoxide
        • Others
      • By Route of Administration
        • Oral Therapy
        • Intravesical Therapy
      • By End User
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Bayer AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Eli Lilly and Co.
    • Johnson & Johnson
    • Mylan NV
    • Novartis AG
    • Perrigo Co. Plc
    • Pfizer Inc.
    • Seikagaku Corp.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drugs
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By End User
      • Market Snapshot, By Region
      • Market Opportunity Map
  3. Global Interstitial Cystitis Drugs Market Insights
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Product Launches
    • Acquisition
    • Epidemiology
    • Recent Product Launches
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Porters Five Force Model
  4. Global Interstitial Cystitis Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Demand and Supply Analysis
  5. Global Interstitial Cystitis Drugs Market, By Drugs, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Pentosan Polysulfate Sodium
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Dimethyl Sulfoxide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  6. Global Interstitial Cystitis Drugs Market, By Route of Administration, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Oral Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Intravesical Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  7. Global Interstitial Cystitis Drugs Market, By End User, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  8. Global Interstitial Cystitis Drugs Market, By Region, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Region at Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth,  By Drugs, 2017–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth,  By Drugs, 2017–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth,  By Drugs, 2017–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2017–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth,  By Drugs, 2017–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2017–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By End User, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Snapshot
    • Company Profiles
      • Bayer AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Eli Lilly and Co.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Johnson & Johnson
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Mylan NV
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Novartis AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Perrigo Co. Plc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Pfizer Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Seikagaku Corp.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
  10. Section
    • Research Methodology
    • About us

*Browse 26 market data tables and 24 figures on " Interstitial Cystitis Drugs Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global interstitial cystitis drugs market size is estimated to be valued at US$ 206.6 Million in 2021 and is expected to exhibit a CAGR of 6.6% between 2021 and 2028.
The high prevalence and increasing awareness of interstitial cystitis, advent of gene therapy, and the rising grants for research on interstitial cystitis will offer immense growth opportunities for the market.
The oral therapy segment is expected to lead the market.
Lack of approved drugs and side-effects of available medications are the major factor restraining growth of the market.
Major players operating in the market include Bayer AG, Eli Lilly and Co., Johnson & Johnson, Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.